Retrospective study shows biologic therapy is safe in patients with a history of malignancy, suggesting it may be a better option than conventional therapies.
Biologic therapy for PsO may represent a safe treatment option in patients with a history of malignancy, compared with conventional systemic therapies or apremilast. Among biologic agents, IL-23 inhibitors appear to be associated with the most favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Gotor‐Rivera et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: